Dedicated to Conquering Heart Failure
A clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease
COVID-19 and CVD
Cardiol received clearance from the FDA for its IND application to commence a Phase II/III clinical trial investigating the efficacy and safety of its lead product, CardiolRx™, in hospitalized COVID-19 patients with a prior history, or risk factors for, cardiovascular disease (CVD).
Learn More
Acute Myocarditis
Cardiol received clearance from the FDA for its IND application for a Phase II international trial CardiolRx™ in acute myocarditis, which remains a leading cause of sudden cardiac death in people under 35 years of age.
Learn More
Heart Failure
Committed to conquering a serious condition that affects more than 26 million people globally.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Therapeutics Announces Closing of US$50 Million Public Offering
November 05, 2021
Cardiol Therapeutics Announces Closing of US$50 Million Public Offering
IN THE MEDIA
In an interview with Pharmacy Times®, Guillermo Torre-Amione, MD, PhD, FACC, the Chairman of Cardiol Therapeutics, discusses the potential use for cannabidiol (CBD) in hospitalized patients with COVID-19, as well as its therapeutic benefits in certain patients with cardiovascular disease.
In this discussion, Dr. Torre-Amione explains the potential benefits for anti-inflammatory therapies for these patients, as well as how CBD specifically can be applied. He also describes a use for CBD in treating cardiovascular disease related to viral damage, and what other anti-inflammatory therapies may soon be available.
TSX:CRDL NASDAQ:CRDL
